Form 4: Director Daniel Pinto Acquires JNJ Deferred Share Units

Johnson & Johnson Director Daniel E. Pinto acquired 1,712 deferred share units as part of the company's director compensation plan.

Summary

• Director Daniel E. Pinto was granted 1,712 Deferred Share Units (DSUs) on April 23, 2026.
• The DSUs were acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors.
• Each DSU represents the fair market value of one share of Johnson & Johnson common stock.
• The units are to be settled in cash upon the termination of the Reporting Person's directorship.
• Following this transaction, the reporting person holds a total of 2,174.069 units, which includes accrued dividend equivalent rights.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that has no impact on the company's operational or financial trajectory.

Positives

• Demonstrates alignment of director interests with long-term shareholder value through equity-based compensation.
• Reflects standard corporate governance practices regarding director fee deferral.

Negatives

• None identified; this is a routine compensatory transaction.

Risks

• Value of the deferred share units is subject to the future market performance of Johnson & Johnson common stock.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a routine disclosure of director compensation.

Industry Context

StockSavvy.ai notes that this filing is a standard regulatory disclosure for director compensation within the pharmaceutical and medical device sector, indicating no change in strategic direction or material financial outlook.

Comparison to Industry Standards

• The use of Deferred Share Units for director compensation is a standard practice among S&P 500 companies to ensure board members maintain a financial stake in the company's performance.
• The disclosure complies with SEC Section 16(a) reporting requirements consistent with industry peers like Pfizer, Merck, and Abbott Laboratories.

Corporate Governance

Stakeholder Impact

• No material impact on shareholders, employees, or creditors.

Next Steps

• The reporting person will continue to hold these units until the termination of their directorship.

Key Dates

Keywords

Johnson & Johnson, JNJ, Director Compensation, Deferred Share Units, Insider Transaction, Form 4